HSV/AAV hybrid amplicon vectors

Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4353201, 435457, 435 691, 435325, 514 44, 424 9321, C12N 1563, C12N 1500, A01N 4304, A61K 3170

Patent

active

059654414

ABSTRACT:
The present invention relates to a hybrid vector system which incorporates elements of herpesvirus and adeno-associated virus and which is capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells.

REFERENCES:
patent: 5254342 (1993-10-01), Shen et al.
patent: 5354844 (1994-10-01), Beug et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5635380 (1997-06-01), Naftilan et al.
patent: 5646034 (1997-07-01), Mamounes et al.
Bett, A.J., et al., "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3,"Proc. Natl. Acad. Sci USA 91:8802-8806 (1994).
Borghesani, P.R., et al., "Genetic Methods for Increasing the Viability of Fetal Mesencephalic Neurons In Vitro and In Vivo," Society for Neuroscience Abstracts 21:2026 (Abstract No. 796.6) (Nov. 1995.).
Cotten, M., et al., "High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles,"Proc. Natl. Acad. Sci USA 89:6094-6098 (1992).
Emi, N., et al., "Pseudotype Formation of Murine Leukemia Virus with the G Protein of Vesicular Stomatitis Virus,"J. Virol. 65(3):1202-1207 (1991).
Friedmann, T., "Gene therapy for neurological disorders,"Trends in Genetics 10: 210-214 (1994).
Janik, J.E., et al., "Efficient Synthesis of Adeno-Associated Virus Structural Proteins Requires Both Adenovirus DNA Binding Protein and VA I RNA,"Virology 168:320-329 (1989).
Johnston, K.M., et al., "HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells,"Hum. Gene Ther. 8(3):359-370 (Feb. 1997).
Jolly, D., "Viral vector systems for gene therapy,"Cancer Gene Therapy 1(1):51-64 (1994).
Kennedy, P.G.E., "Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders," Brain 120:1245-1259 ( Jul. 1997).
Landau, N.R. and D.R. Littman, "Packaging System for Rapid Production of Murine Leukemia Virus Vectors with Variable Tropism," J. Virology 66(8):5110-5113 (1992).
Michael, S.I. and D.T. Curiel, "Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway,"Gene Ther. 1:223-232 (1994).
Miller, A.D., et al., "Factors Involved in Production of helper Virus-Free Retrovirus Vectors,"Somatic Cell Mol. Gen 12(2): 175-183 (1986).
Mitani, K., et al., "Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector,"Proc. Natl. Acad. Sci. USA 92:3854-3858 (Apr. 1995).
Mulligan, R.C., "The Basic Science of Gene Therapy," Science 260:926-932 (1993).
Muzyczka, N., "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," Curr. Topics Microbiol. Immunol. 158:97-129 (1992).
Naldini, L., et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," Science 272:263-267 (Apr. 1996).
Orkin, S.H. and A.G. Motulsky, "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," pp. 1-40 (Dec. 1995).
Samulski, R.J., "Adeno-associated virus: integration at a specific chromosomal locus," Curr. Opin. Genet. Dev. 3:74-80 (1993).
Smith, F., et al., "Virus vectors for gene delivery to the nervous system," Rest. Neurol. Neurosci. 8: 21-34 (Jun. 1995).
Strair, R.K., et al., "Retroviral mediated gene transfer into bone marrow progenitor cells: use of beta-galactosidase as a selectable marker,"Nucleic Acids Res. 18(16):4759-4762 (1990).
von Ruden, T., et al., "Generation of High-Titer Retroviral Vectors Following Receptor-Mediated, Adenovirus-Augmented Transfection," Biotechniques 18(3):484-489 (Mar. 1995).
Wagner, E., et al., "Coupling of Adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," Proc. Natl. Acad. Sci. USA 89:6099-6103 (1992).
Wang, S. and J.-M. Vos, "A Hybrid Herpesvirus Infectious Vector Based on Epstein-Barr Virus and Herpes Simplex Virus Type 1 for Gene Transfer into Human Cells In Vitro and In Vivo," J. Virol. 70(12):8422-8430 (Dec. 1996).
Webster, A., et al., "The Adenovirus Protease is Activated by a Virus-Coded Disulphide-Linked Peptide," Cell 72:97-104 (1993).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

HSV/AAV hybrid amplicon vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HSV/AAV hybrid amplicon vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HSV/AAV hybrid amplicon vectors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-651720

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.